GlaxoSmithKline will expand production of vaccine efficacy boosters, or adjuvants, to produce 1 billion doses in 2021 for use in shots for Covid-19, the British drugmaker said today.
The company said it was in talks with governments on backing for the programme, which would effectively allow for a scaling up of production of future successful vaccines for the disease caused by the coronavirus.
GSK is one of several companies in the race to develop a vaccine for the respiratory illness that currently has no treatment and has already killed about 350,000 people.
The London-listed drugmaker is working on its own Covid vaccine with Sanofi. Adjuvants have been shown to create a stronger and longer-lasting immunity against infections.